Vident Advisory, LLC Kymera Therapeutics, Inc. Transaction History
Vident Advisory, LLC
- $5.7 Trillion
- Q4 2024
A detailed history of Vident Advisory, LLC transactions in Kymera Therapeutics, Inc. stock. As of the latest transaction made, Vident Advisory, LLC holds 5,863 shares of KYMR stock, worth $215,817. This represents 0.0% of its overall portfolio holdings.
Number of Shares
5,863Holding current value
$215,817% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding KYMR
# of Institutions
186Shares Held
65.5MCall Options Held
49.6KPut Options Held
17K-
Price T Rowe Associates Inc Baltimore, MD6.87MShares$253 Million0.03% of portfolio
-
Baker Bros. Advisors LP New York, NY6MShares$221 Million2.67% of portfolio
-
Wellington Management Group LLP Boston, MA5.31MShares$195 Million0.04% of portfolio
-
Bvf Inc San Francisco, CA5.16MShares$190 Million7.77% of portfolio
-
Avoro Capital Advisors LLC New York, NY5.15MShares$190 Million3.02% of portfolio
About Kymera Therapeutics, Inc.
- Ticker KYMR
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 54,705,800
- Market Cap $2.01B
- Description
- Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunolo...